Treatment with bisphosphonates and atypical fractures;Tratamiento con bisfosfonatos y fracturas atipicas

Medicina

Volumn 69, Issue 6, 2009, Pages 612-618

  Spivacow, Francisco R ^a   Sarli, Marcelo ^a   Buttazzoni, Mirena ^b  

^a UNIVERSIDAD DEL SALVADOR   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Atraumatic fractures; Bisphosphonates side effects; Severely suppressed bone turnover

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; FLUOROPHOSPHATE; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; SIMVASTATIN; TYROSINE; VITAMIN D;

AGED; ARTICLE; BONE TURNOVER; CASE REPORT; FEMALE; FEMUR SHAFT FRACTURE; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; MORPHOMETRICS; OSTEOPENIA; OSTEOPOROSIS; PELVIS FRACTURE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PELVIS;

EID: 75149126061     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59.
2. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85: 4118-24.
3. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the Treatment of Osteoporosis in Men. N Engl J Med 2000; 343: 604-10.
4. Ott SM. Editorial: Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90(3): 1897-9.
5. Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 1984; 304: 509-18.
6. Odvina C, Zerwekh J, Sudhaker Rao D, Maalouf N, Gottschalk F, Pak CYC. Severely suppressed bone turnover: A potential complication of alendronate therapy. The Journal of Clinical Endocrinology & Metabolism 2005; 90: 1294-301.
7. Tonino R, Santora A, Ross P. Safety of long-term alendronate. J Clinil Endocrinol Metab 2001; 86: 1835-6.
8. Lenart B, Lorich D, Lane J. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Eng N Engl y Med 2008; 358: 1304-06.
9. Visekruna M, Wilson D, McKiernan F. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93: 2948-52.
10. Goh S, Yang K, Koh J, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. A caution. J Bone Joint Surg [Br] 2007; 89-B: 349-53.
11. Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007; 25: 333-6.
12. Whyte M, Wenkert D, Clemens K, McAllister W, Mumm S. Bisphosphonate- induced osteopetrosis. N Engl J Med 2003; 349: 457-63.
13. Weinstein R, Chambers T, Hogan E, Webb W, Wicker C, Manolagas S. Giant osteoclast formation after long-term oral aminobisphosphonate therapy for postmenopausal osteoporosis. J Bone Miner Res 2007; 22(Suppl 1): S17.
14. Mellström D, Sörensen O, Goemaere S, Roux C, Johnson T, Chines A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75: 462-8.
15. Bone H, Hosking D, Devogelaer J, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
16. Ensrud K, Barrett-Connor E, Schwartz A, et al. Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. Bone Miner Res 2004; 19: 1259-69.
17. Black D, Schwartz A, Ensrud K, et al. Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. The Fracture InterventionTrial Long-term Extension (FLEX): A Randomized Trial. JAMA 2006; 296: 2927-38.